Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Combining drugs and extending treatment — a PFS end point is not sufficient

In studies investigating the combination of two or more anticancer drugs that are already approved for independent use, or 'maintenance' regimens, the use of progression-free survival as the end point for approval is inadequate; sequential treatment with the same agents or existing salvage therapies, respectively, might provide an equivalent survival benefit, with lower toxicity, cost, and treatment burden, therefore, the use of an overall survival end point is essential to justify such interventions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Prasad, V., Kim, C., Burotto, M. & Vandross, A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern. Med. 175, 1389–1398 (2015).

    Article  Google Scholar 

  2. Booth, C. M. & Eisenhauer, E. A. Progression-free survival: meaningful or simply measurable? J. Clin. Oncol. 30, 1030–1033 (2012).

    Article  Google Scholar 

  3. Mailankody, S. & Prasad, V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 1, 539–540 (2015).

    Article  Google Scholar 

  4. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

    Article  Google Scholar 

  5. Hanna, N. H. et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann. Oncol. 13, 95–102 (2002).

    Article  CAS  Google Scholar 

  6. Goodwin, J. S. Routine cancer antigen 125 surveillance — the fatal attraction of testing. JAMA Oncol. 2, 1412–1413 (2016).

    Article  Google Scholar 

  7. Moskowitz, C. H. et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385, 1853–1862 (2015).

    Article  CAS  Google Scholar 

  8. Sweetenhan, J. W. et al. Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse [abstract]. Biol. Blood Marrow Transplant. 22, S36 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Vinay Prasad.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Selected studies of combination and maintenance therapies in oncology (DOC 56 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gyawali, B., Prasad, V. Combining drugs and extending treatment — a PFS end point is not sufficient. Nat Rev Clin Oncol 14, 521–522 (2017).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer